156
Participants
Start Date
July 31, 2012
Primary Completion Date
April 4, 2019
Study Completion Date
February 2, 2022
LY3023414
Administered orally. Dose of 20 to 600 mg, as determined in Part A.
Midazolam
0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
Fulvestrant
500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
Pemetrexed
500 mg/m2 administered IV once on Day 1 every 21 days
Cisplatin
75 mg/m2 administered IV once on Day 1 every 21 days
Abemaciclib
Administered orally
Letrozole
Administered orally
Azienda Ospedaliero - Universitaria S. Luigi Gonzaga, Orbassano
Memorial Sloan Kettering Cancer Center, New York
Penn Presbyterian Medical Center, Philadelphia
Sarah Cannon Cancer Center, Nashville
Tennessee Oncology PLLC, Nashville
Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City
UCLA Medical Center, Los Angeles
Fundacion de Investigacion de Diego, San Juan
Eli Lilly and Company
INDUSTRY